Shares of Sientra (NASDAQ:SIEN) have received a consensus rating of “Buy” from the ten research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $16.00.
A number of analysts recently issued reports on SIEN shares. ValuEngine raised shares of Sientra from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Maxim Group increased their price target on shares of Sientra from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Thursday, April 26th. Canaccord Genuity lowered their price target on shares of Sientra from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, March 14th. BidaskClub raised shares of Sientra from a “hold” rating to a “buy” rating in a report on Tuesday, May 1st. Finally, Lake Street Capital increased their price target on shares of Sientra from $11.00 to $13.00 and gave the stock a “hold” rating in a report on Thursday, April 19th.
Get Sientra alerts:Shares of SIEN stock traded down $0.01 during trading hours on Monday, hitting $17.01. The company’s stock had a trading volume of 326,132 shares, compared to its average volume of 933,663. The company has a market capitalization of $479.67 million, a P/E ratio of -6.03 and a beta of -1.11. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.21 and a quick ratio of 0.71. Sientra has a 12-month low of $7.34 and a 12-month high of $18.09.
Sientra (NASDAQ:SIEN) last released its quarterly earnings data on Wednesday, May 9th. The medical instruments supplier reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.15). The business had revenue of $14.60 million during the quarter, compared to analysts’ expectations of $14.49 million. Sientra had a negative net margin of 164.72% and a negative return on equity of 181.25%. The firm’s revenue was up 95.2% on a year-over-year basis. During the same period last year, the company earned $0.61 earnings per share. sell-side analysts forecast that Sientra will post -2.72 earnings per share for the current year.
In related news, Director R Scott Greer acquired 11,111 shares of Sientra stock in a transaction on Monday, May 7th. The stock was bought at an average cost of $13.50 per share, for a total transaction of $149,998.50. Following the completion of the transaction, the director now owns 52,657 shares of the company’s stock, valued at approximately $710,869.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Jeffrey M. Nugent acquired 1,852 shares of Sientra stock in a transaction on Monday, May 7th. The shares were bought at an average price of $13.50 per share, with a total value of $25,002.00. Following the completion of the transaction, the chairman now directly owns 299,851 shares of the company’s stock, valued at approximately $4,047,988.50. The disclosure for this purchase can be found here. Insiders have purchased 301,853 shares of company stock worth $4,075,016 over the last three months. 31.00% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of the business. Cannell Capital LLC raised its position in Sientra by 15.8% during the first quarter. Cannell Capital LLC now owns 1,158,485 shares of the medical instruments supplier’s stock worth $11,191,000 after acquiring an additional 158,058 shares during the period. BlackRock Inc. raised its position in Sientra by 1.2% during the first quarter. BlackRock Inc. now owns 767,308 shares of the medical instruments supplier’s stock worth $7,411,000 after acquiring an additional 8,796 shares during the period. Bamco Inc. NY raised its position in Sientra by 20.0% during the first quarter. Bamco Inc. NY now owns 588,100 shares of the medical instruments supplier’s stock worth $5,681,000 after acquiring an additional 98,000 shares during the period. Senzar Asset Management LLC raised its position in Sientra by 9.2% during the first quarter. Senzar Asset Management LLC now owns 529,210 shares of the medical instruments supplier’s stock worth $5,112,000 after acquiring an additional 44,603 shares during the period. Finally, Millennium Management LLC acquired a new position in Sientra during the first quarter worth $4,287,000. Institutional investors own 82.10% of the company’s stock.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
No comments:
Post a Comment